The objective response rate was doubled by the addition of tucatinib to trastuzumab and capecitabine in HER2+ BC patients with BMs, reducing the risk of intracranial progression or death by two-thirds, and reducing the risk of death by nearly half [131]. The gene discussed is ERBB2; the disease is breast cancer.